Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 10
2018 94
2019 272
2020 214
2021 75
Text availability
Article attribute
Article type
Publication date

Search Results

548 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W; SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Wolraich ML, et al. Pediatrics. 2019 Oct;144(4):e20192528. doi: 10.1542/peds.2019-2528. Pediatrics. 2019. PMID: 31570648 Free PMC article.
Attention-deficit/hyperactivity disorder (ADHD) is 1 of the most common neurobehavioral disorders of childhood and can profoundly affect children's academic achievement, well-being, and social interactions. The American Academy of Pediatrics first published clinical recomm …
Attention-deficit/hyperactivity disorder (ADHD) is 1 of the most common neurobehavioral disorders of childhood and can profoundly affect chi …
Innovation During COVID-19: Improving Addiction Treatment Access.
Samuels EA, Clark SA, Wunsch C, Jordison Keeler LA, Reddy N, Vanjani R, Wightman RS. Samuels EA, et al. J Addict Med. 2020 Jul/Aug;14(4):e8-e9. doi: 10.1097/ADM.0000000000000685. J Addict Med. 2020. PMID: 32404652 Free PMC article.
The value of harm reduction for injection drug use: A clinical and public health ethics analysis.
Vearrier L. Vearrier L. Dis Mon. 2019 May;65(5):119-141. doi: 10.1016/j.disamonth.2018.12.002. Epub 2018 Dec 29. Dis Mon. 2019. PMID: 30600096
This analysis concludes that harm reduction is ethically sound and should be an integral aspect of our nation's healthcare system for combating the opioid crisis. From a clinical ethics perspective, harm reduction promotes the autonomy of, prevents harms to, advances the w …
This analysis concludes that harm reduction is ethically sound and should be an integral aspect of our nation's healthcare system for …
Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Samet JH, Saxon AJ, Campbell CI, Glass JE, Rossom RC, Murphy MT, Binswanger IA, Yarborough BJH, Bradley KA; PROUD Collaborative Investigators. Lapham G, et al. Drug Alcohol Depend. 2020 Feb 1;207:107732. doi: 10.1016/j.drugalcdep.2019.107732. Epub 2019 Nov 15. Drug Alcohol Depend. 2020. PMID: 31835068 Free PMC article. Clinical Trial.
BACKGROUND: The U.S. experienced nearly 48,000 opioid overdose deaths in 2017. Treatment of opioid use disorder (OUD) with buprenorphine is a recommended part of primary care, yet little is known about current U.S. practices in this setting. ...
BACKGROUND: The U.S. experienced nearly 48,000 opioid overdose deaths in 2017. Treatment of opioid use disorder (OUD) with buprenorph …
Introduction to the special issue.
Finlay A, Binswanger I, Timko C. Finlay A, et al. Addict Sci Clin Pract. 2020 Feb 5;15(1):5. doi: 10.1186/s13722-020-0182-0. Addict Sci Clin Pract. 2020. PMID: 32019590 Free PMC article.
548 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page